IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

January 09, 2026
Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says

Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.
January 02, 2026
SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026

The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as well as bellwether trials in multidistrict litigation concerning social media's effects on mental health and allegations of price-fixing in the generic-drug industry.
December 09, 2025
Meet The Attys For Humana In Price-Fixing MDL Set For Trial

Attorneys from Lowey Dannenberg PC and Schneider Wallace Cottrell Kim LLP are teaming up to represent insurance giant Humana in the first bellwether case set for trial in multidistrict litigation accusing pharmaceutical companies of fixing generic drug prices.
December 03, 2025
AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing

AT&T has joined the bevy of litigants suing a swath of pharmaceutical companies over alleged generic drug price-fixing, claiming it shelled out billions of dollars for medication reimbursements to the drugmakers as part of its employee health plans when it could have spent far less if the drugs weren't subject to anticompetitive pricing.
December 03, 2025
AGs Say Sun, Taro Settlement Mustn't Touch State Claims

State attorneys general have asked a Pennsylvania federal judge to again ensure their claims remain untouched by a settlement between private plaintiffs and generic-drug makers in sprawling price-fixing litigation, this time focusing on a $200 million deal between Sun Pharmaceutical, Taro Pharmaceuticals and employee benefit plans.
November 20, 2025
Claims Firms Barred From Misleading Plaintiffs In Pharma MDL

On the same day that a Philadelphia federal judge approved $58 million in settlements as part of an ongoing generic-drug price-fixing multidistrict litigation, she also ordered several claims recovery firms to correct allegedly false and misleading ads used to attract potential clients seeking to make claims on the settlements.
November 14, 2025
Drug Buyers Defend Class Cert. In 3rd Circ. Generics Case

Direct purchasers and end-payers in the sprawling multidistrict litigation over alleged price-fixing of generic drugs are fighting requests from Actavis and Mylan to undo class certification in the cases, arguing to the Third Circuit that the litigation is a classic example of a class action matter.
November 13, 2025
Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL

A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.
November 04, 2025
End Payors Seek $66M In Atty Fees In Generic Drug MDL

End payors in a generic drug price-fixing multidistrict litigation are seeking a Pennsylvania federal court's approval for a $66 million award of attorney fees, representing one-third of the $200 million settlement between the classes and Sun Pharmaceutical Industries Inc. and Taro Pharmaceuticals USA Inc.
November 03, 2025
Pharmacies Seek Cert. In Cholesterol Drug Price-Fixing MDL

A group of indirect reseller plaintiffs urged a Pennsylvania federal judge on Friday to certify a nationwide class of thousands of pharmacies that indirectly purchased the cholesterol medication pravastatin in sprawling multidistrict litigation over alleged price-fixing in the generic drug industry.

← Previous
1
2
3
4
5
6
7
8
9
…
Next →